The low-density lipoprotein receptor (LDLr) plays a pivotal role in cholesterol homeostasis. Mutations in the LDLr gene (LDLR), which is located on chromosome 19, cause familial hypercholesterolemia (FH), an autosomal dominant disorder characterized by severe hypercholesterolemia associated with premature coronary atherosclerosis. To date almost 300 mutations have been identified in the LDLR gene. To facilitate the mutational analysis of the LDLR gene, and promote the analysis of the relationship between genotype and phenotype, a software package along with a computerized database (currently listing 210 entries) have been created.
INTRODUCTION
The low-density lipoprotein receptor (LDLr) is an ubiquitous transmembrane glycoprotein of 839 amino acids that mediates the transport of LDL into cells, via receptor-mediated endocytosis, and is pivotal in cholesterol homeostasis (1) . Defects in the LDLr result in familial hypercholesterolemia (FH). FH is characterized clinically by raised plasma LDL-cholesterol concentrations, xanthomas and early coronary heart disease (2) . FH is an autosomal dominant trait, homozygotes being more severely affected than heterozygotes. FH is also one of the most common inherited disorders with a frequency of heterozygotes estimated to be 1:500 and a frequency of homozygotes being ∼1:10 6 in most populations. FH frequency is higher in certain communities in which a small number of mutations predominate due to founder effects. These communities include French Canadians (3), Christian Lebanese (4), Druze (5), Finns (6), Afrikaners (7) and Ashkenazi Jews of Lithuanian descent (8) .
The gene for the LDL receptor (LDLR) located at chromosome 19p13. 1-13.3 (9) , spans 45 kb, and is divided into 18 exons (10) . The correspondence between gene exons and functional domains of the mature protein is well established (10) . Exon 1 encodes the 21 amino acids of the signal sequence which is cleaved from the protein during translocation into the endoplasmic reticulum (ER).
Exons 2-6 encode the ligand-binding domain, which is made up of seven repeats of 40 amino acids each. These repeats are homologous to sequences of the protein C9 of the complement cascade (10) . Each repeat contains six cysteine residues that form three disulfide bonds. The C-terminal end of each repeat contains a negatively charged triplet, SDE, important for ligand binding. Exons 7-14 encode a 400 amino acids sequence that is 33% identical to a portion of the human epidermal growth factor (EGF) precursor gene. This region includes three growth factor repeats which are 40 amino acid cysteine-rich sequences that differ from the cysteine-rich sequences in the ligand-binding domain. The two first repeats are contiguous and separated from the third by a 28 amino acids sequence that contains five copies of a conserved motif (YWTD) repeated once each 40-60 amino acids (10) . This domain is required for the dissociation of lipoproteins from the receptor in the endosome during receptor recycling. It also serves to position the ligand binding domain so that it can bind LDL on the cell surface (11) . Exon 15 encodes 58 amino acids that are enriched in serine and threonine residues, which serve as attachment sites for O-linked sugar chains. Absence of this exon has no significant functional consequence in cultured hamster fibroblasts (12) . The 3′ end of exon 16 and the 5′ end of exon 17 encode the 22 hydrophobic amino acids of the membrane-spanning domain. The remainder of exon 17 and the 5′ end of exon 18 encode the 50 amino acids that make up the cytoplasmic domain. This domain is important for the localization of the receptor in coated pits on the cell surface (12) (13) (14) . The remainder of exon 18 specifies the 2.6 kb 3′ untranslated region of the mRNA.
In normal fibroblasts, an LDLr precursor protein (120 kDa) is produced in the ER. Within 30 min the protein (160 kDa) is transported to the Golgi complex. From the Golgi complex, the receptor is transported then to the cell surface where it binds its ligand, LDL, and is internalized by endocytosis (1) . Mutations in the LDLR gene have been classified into five functional groups based on the characteristics of the LDLr produced (15) . Class 1 mutations disrupt the receptor's synthesis in the ER. Class 2 mutations block transport to the Golgi complex: class 2A mutations completely block receptor transport, while class 2B mutations produce proteins that are transported at a detectable, Table 1 . Each line represents a single LDLR mutation. The columns contain the following information and abbreviations A: File number. B: Exon number in which the mutation occurred. Exons are numbered according to Südhof et al. (10) with respect to the translational initiation site given by Yamamoto et al. (80) . C: Nucleotide position in which the mutation occurred. D: Codon number in which the mutation occurred. Codons are numbered according to Yamamoto et al. (80) . Therefore, the 21 amino acids of the signal peptide (exon 1) are numbered in negative (from -21 to -1). Codon number 1 is the last codon of exon 1 and encodes the first amino acid (Ala) of the mature LDLr protein.
If the mutation spans more than one codon, e.g. there is a deletion of several bases, only the first (5′) deleted codon is entered. E: Normal base sequence of the codon in which the mutation occurred. F: Mutated base sequence of the codon in which the mutation occurred. If the mutation is a base pair deletion or insertion, this is indicated by « del »or « ins » followed by the number of bases deleted or inserted and the position of this deletion or insertion in the codon (a, b or c). The nucleotide position is the first that is deleted or the one preceding the insertion. For example, « del12c » is a deletion of 12 bases including the third base of the codon, « ins8b » is an insertion of eight bases occurring between the second and the third base of the codon. G: Concerns base substitutions. It gives the base change, by convention, read from the coding strand. If the mutation predicts a premature protein termination, the novel stop codon position is given, e.g. « stop at 204 ». H: Mutation name according to Beaudet et al. (81) . Missense mutations are designated by the codon number flanked by the single letter code of the normal amino acid prior and of the mutant amino acid after (e.g. Val to Met at codon 408 is designated « V408M »). Nonsense mutations are designated similarly except that X is used to indicate any termination codon (e.g. Tyr to stop at codon 167 is designated « Y167X »). Frameshift, insertion and deletion mutations are designated by the nucleotide number followed by 'ins' for insertion or 'del' for deletion. The nucleotide position is the first that is deleted or the one preceding it in the case of insertions. Exact nucleotides are indicated for two or less bases (e.g. 7delG). For three or more bases, the insertion or deletion is specified by the size of the change (e.g. 661del21 indicates a 21 pb deletion starting from nucleotide 661). For many of the mutations that have been reported this nomenclature has not been used. Therefore, the original name also appears in this column. These names were given according to the population or the city in which the mutation was reported first, e.g. O: Number of the file in which the second mutation identified in a compound heterozygote is described. When the second mutation is one of those omitted in the database, this mutation is briefly described with respect to the coding sequence. Finally, « ? » indicates that the second mutation has not been identified. P: Recurrence of the mutation. « F » designates a founder effect, « DN » designates a de novo mutation found in a proband, but not carried by the proband's parents, « R » designates recurrent mutations, and « ? » mutations that have been identified in at least two unrelated probands of different ethnic backgrounds but for which LDLR gene haplotypes are not described. Empty cases designate mutations identified in a single proband. Q: Ethnic background of the proband. R: Reference number indicating the publication in which the mutation is described. Full citations (authors, year, title, journal, volume, pages) are provided with the database. If the same mutation has been reported for the same patient in different papers, only one entry is made. If the same mutation has been reported for unrelated patients (recurrent mutations), a separate entry is made for each patient. Note: The present version of the database cannot accommodate two mutational events in a given allele, therefore the compound insertion-deletions reported by Yamakawa-Kobayashi et al. (82) but markedly reduced rate. Class 3 mutations produce proteins that are transported to the cell surface, but fail to bind LDL normally. Class 4 mutations affect the cytoplasmic domain alone (4A) or also the membrane-spanning region (4B). They produce proteins that cannot internalize bound LDL into the cell. Finally, Class 5 mutations block the acid-dependent dissociation of receptor and ligand in the endosome, an essential event for receptor recycling (16) .
Through an extensive survey of the literature we found that 302 mutations have been reported in the LDLR gene. Among these, only 72 (∼25%) are major rearrangements. Therefore the majority of FH-causing mutations are either small deletions/insertions/duplications or point mutations. With the exception of « founder » gene mutations, many mutations are extremely rare and have been identified in single families only. In effect, true recurrence has only been conclusively demonstrated in a few cases. While much effort has been put into the identification of molecular defects in the LDLR gene, few teams (except Hobbs and coworkers) (16) have explored their functional implication and hardly no effort has been made to investigate genotype/phenotype relationships. In this perspective, and to facilitate the mutational analysis of the LDLR gene, we have compiled a database and created a software package for its analysis.
DATABASE AND SOFTWARE
In an effort to standardize the information regarding LDLr mutations, we have created a computerized database that currently contains information about the published mutations of the LDLr gene. The current version of the database contains 210 entries (3) (4) (5) (6) 8, . Major rearrangements, as well as the six mutations in the promoter sequence (16, (72) (73) (74) , the 14 splice mutations (16, 44, 46, 47, (75) (76) (77) (78) and polymorphisms were omitted as they cannot be accommodated in the present version of the software. For each mutation, information is provided at several levels: at the gene level (exon and codon number, wild type and mutant codon, mutational event, mutation name), at the mRNA level (size, processing), at the protein level (wild type and mutant amino acid, affected domain, activity, mutation class), and at the personal level (ethnic background, age, sex, body mass index and familial history of coronary heart disease). Table 1 gives part of the database in Excel spreadsheet format.
The software package contains routines for the analysis of the LDLR database that were developed with the 4th dimension R (4D) package from ACI. The use of the 4D SGDB gives access to optimized multicriteria research and sorting tools to select records from any field. Moreover, six routines were specifically developed: (i) 'Position' studies the distribution of mutations at the nucleotide level to identify preferential mutation sites; (ii) 'Statistical evaluation of mutational events' is comparable with (i) but also indicates the type of mutational event. The result can either be displayed as a table or in a graphic representation; (iii) 'Frequency of mutation' allows one to study the relative distribution of mutations at all sites and to sort them according to their frequency. A graphic representation is also available and displays a cumulative chart of mutation distribution; (iv) 'Stat exons' studies the distribution of mutations in the different exons. It enables detection of a statistically significant difference between observed and expected mutations. (v) 'Protein' studies the distribution of mutational events in various protein domains (ligand-binding and EGF-precursor-like motifs), and aligns the amino acids of the consensus sequence for each domain type. (vi) 'Insertions and deletions analysis' searches for repeated sequences surrounding the mutation and possibly involved in the mutational mechanism.
The present version of the database contains no clinical data as these are incompletely given in almost all mutation reports that have been published. However, as the purpose of this database is to promote not only the molecular analysis of mutational events within the LDLR gene, but also genotype/phenotype relationships, the database will be expanded in the future to include clinical data (symptomatic coronary artery disease, xanthomas) and biological data (total plasma cholesterol and LDL-cholesterol before or without treatment), as well as the ages at which they were assessed and, when appropriate, the age of death. Furthermore, data should also be available concerning therapy. Finally, the software will be expanded as the database grows and according to the requirements of its users. New functions could be implemented comparable with those already available in the APC gene mutations database (79) .
AVAILABILITY
The current database and subsequent updated versions are (will be) available on request from M.V. and C. Bo. on floppy disc using Apple format and Microsoft Excel R . Notification of omissions and errors in the current version as well as specific phenotypic data would be gratefully received by the corresponding authors. The software package is available on a collaborative basis.
